Cargando…
Generalizability of treatment outcome prediction in major depressive disorder using structural MRI: A NeuroPharm study
Brain morphology has been suggested to be predictive of drug treatment outcome in major depressive disorders (MDD). The current study aims at evaluating the performance of pretreatment structural brain magnetic resonance imaging (MRI) measures in predicting the outcome of a drug treatment of MDD in...
Autores principales: | Beliveau, Vincent, Hedeboe, Ella, Fisher, Patrick M., Dam, Vibeke H., Jørgensen, Martin B., Frokjaer, Vibe G., Knudsen, Gitte M., Ganz, Melanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668596/ https://www.ncbi.nlm.nih.gov/pubmed/36252556 http://dx.doi.org/10.1016/j.nicl.2022.103224 |
Ejemplares similares
-
Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study
por: Dam, Vibeke Høyrup, et al.
Publicado: (2022) -
Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study
por: Köhler-Forsberg, Kristin, et al.
Publicado: (2022) -
The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study
por: Larsen, Søren Vinther, et al.
Publicado: (2022) -
Stress Hormone Dynamics Are Coupled to Brain Serotonin 4 Receptor Availability in Unmedicated Patients With Major Depressive Disorder: A NeuroPharm Study
por: Vulpius, Gunild M, et al.
Publicado: (2023) -
Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol
por: Köhler-Forsberg, Kristin, et al.
Publicado: (2020)